SynAct Pharma signs Brazilian resomelagon dengue partnership with Hipolabor on 50-50 profit-sharing terms
SynAct Pharma has formalised a Brazilian partnership with Hipolabor to develop and commercialise investigational resomelagon for dengue treatment under a 50-50 cost and profit-sharing structure.
The definitive agreement follows an August term sheet and provides for equal sharing of development costs and future commercial profits from resomelagon in the Brazilian dengue market.
The arrangement also includes sales milestone payments linked to cumulative net sales of $200 million, with payment amounts undisclosed, while SynAct retains rights outside the specified indication and territory.
Field | Content |
Article Type | Deals |
Companies | SynAct Pharma; Hipolabor |
Deal Type | Definitive co-development and commercialisation agreement |
Announcement Date | 27 October 2026 |
Previous Agreement Stage | Term sheet announced in August 2026 |
Development Asset | Resomelagon |
Therapeutic Area | Infectious diseases |
Target Indication | Dengue |
Territory | Brazil |
Development Cost Sharing | 50% SynAct Pharma; 50% Hipolabor |
Future Commercial Profit Sharing | 50% SynAct Pharma; 50% Hipolabor |
Sales Milestone Structure | Milestone payments linked to cumulative net sales of $200 million |
Sales Milestone Payment Amounts | Not disclosed |
Upfront Payment | Not disclosed |
Rights Outside Territory | Retained by SynAct Pharma outside the agreed territory and indication |
Product Regulatory Status | Investigational; no dengue treatment approval established by this agreement |
What Happened | SynAct Pharma and Hipolabor signed a definitive agreement to co-develop and commercialise resomelagon for dengue in Brazil. |
Why It Matters | The partnership establishes a regional development and commercialisation framework for an investigational dengue therapy, sharing both financial risk and potential returns. |
Strategic Rationale | Combine SynAct's development asset with Hipolabor's Brazilian market capabilities while sharing programme costs and commercial profits equally. |
Financial Structure | Equal cost and profit sharing plus sales milestone payments; milestone amounts were not disclosed. |
Key Takeaway | SynAct and Hipolabor have formalised a Brazil-specific dengue partnership with 50-50 economic sharing, but resomelagon remains investigational. |
What to Watch | Clinical development plans, Brazilian regulatory interactions, programme financing, potential marketing authorisation and future sales milestones. |
Primary Source | SynAct Pharma |
Primary Source URL | https://www.synactpharma.com/en/?p=27624 |
Relevant Date | 27 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários